Switching of integrase inhibitors (dolutegravir, raltegravir and elvitegravir) due to adverse events to other antiretroviral treatments in patients with HIV infection: A three retrospective study
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Dolutegravir (Primary) ; Elvitegravir (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 30 Aug 2017 New trial record
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science